UK Could Block Activist Plans To Shake Up GSK
New Law Allows Intervention
Executive Summary
GlaxoSmithKline is under attack from an activist investor, but as a key UK company, the government could use new powers to block any deals “not in the national interest”.
You may also be interested in...
Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.
Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.